Regenosca provides regenerative medicine technology that enables permanent regrowth of your own native tissues on a self-absorbing mesh, ensuring seamless healing of soft tissue defects and surgical wounds. Our solutions are cost-effective, safe, and designed with surgeons in mind.
TissueSpan is an innovative, natural mesh, designed to support seamless soft tissue repair and function as a protective barrier. While not a living tissue, it is engineered to actively attract and organize the patient’s own cells upon implantation, initiating the body’s natural regenerative processes. Fully absorbable, off-the-shelf, and ready-to-use, TissueSpan ensures easy clinical translation and compatibility with current surgical techniques.
Swiss Medtech startups reach key development milestones (startupticker.ch)
Auszeichnungen, Accelerator-Zugang und Förderungen für Startups (startupticker.ch)
Fresh funding for Regenosca (startupticker.ch)
Innosuisse recognizes startups envisioned to transform the medical sector (startupticker.ch)
Swiss Medtechs seek growth opportunities in Boston (startupticker.ch)
Venture Leaders Medtech 2023: 10 innovative startups will advance their global growth in Boston (venturelab.swiss)
Les meilleures startups suisses de Bilan révélées (startupticker.ch)
Regenosca wins CHF 150,000 to support bladder reconstruction (startupticker.ch)
Medtech and Cleantech startups get boosted (startupticker.ch)
Membrasenz ravit le Trophée PERL 2020 (startupticker.ch)
All patients of First-in-Man study operated
All patients of First-in-Man study operated
KOL is joining First-in-Man study as investigator
Closing of Seed Round
Closing of convertible loan with private investors
First patients operated in a First-in-Man study
First patients operated in a First-in-Man study
Closing of convertible loan with private investors
Regenosca's patent is granted in the US
Regenosca's patent is granted in the US
Regenosca's patent is granted in Europe